Adaptive Biotechnologies Corporation
NASDAQ:ADPTBiotechnology
+$0.61 today
- Market cap
- $4.61B
- Beta
- 2.15
- P/E (TTM)
- -54.5
- EPS (TTM)
- -$0.32
Volume 2.21M
Average 1.94M
ADPT Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Adaptive Biotechnologies CorporationNASDAQ: ADPT
Short-term Investments · Q2 FY2026 · quarter ended Jun 2026
Short-term investments rises 12.7% from a year ago
Short-term investments stood at $174.38M at the end of Q2 FY2026, up 12.7% from a year earlier and up 23.9% from the prior quarter. Over 3 fiscal years it compounded at -27.4% a year.
Context
- Short-term investments amounted to 27.2% of total assets at the end of Q2 FY2026, down 3.9 pp from a year earlier.
- Short-term investments increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether short-term investments keeps rising in the next quarterly balance sheet after a +12.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 156.49M USD
- Year-over-year change
- -10.3%
- 4-year CAGR
- -7.5%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 156.49M | -10.3% |
| FY2024 | 2024-12-31 | 174.37M | -38.0% |
| FY2023 | 2023-12-31 | 281.34M | -31.1% |
| FY2022 | 2022-12-31 | 408.17M | +90.7% |
| FY2021 | 2021-12-31 | 214M | — |
Short-term Investments vs competitors
How ADPT compares with its peers on the latest reported figures
- ADPT's Jun 2026 short-term investments of $174.38M is the 6th highest of the 10 companies compared; the peer median is $391.8M.
- Its year-over-year change of +12.7% is the 3rd highest of 8, against a peer median of -8.7%.
- Short-term investments amounts to 27.2% of total assets for ADPT, versus a peer median of 34.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $933.1M | +7.5% | +4.0% | 67.3% | |
IRONDisc Medicine, Inc. | Sep 2026 | $592.83M | +24.7% | — | 84.8% |
| Jun 2026 | $523.14M | +134.5% | +178.4% | 78.3% | |
| Mar 2026 | $513.68M | -8.7% | +21.1% | 49.9% | |
| Sep 2026 | $391.8M | -45.1% | -42.0% | 23.3% | |
| Jun 2026 | $174.38M | +12.7% | -27.4% | 27.2% | |
| Sep 2026 | $173.08M | -40.1% | +17.1% | 34.2% | |
| Sep 2026 | $47.33M | -42.9% | -40.8% | 10.6% | |
| Jun 2026 | $10M | — | — | 0.9% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ADPT) | $391.8M | -8.7% | +10.6% | 34.2% | |
Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 139.07M | 90.03M | 65.06M | 47.92M | 70.5M |
| Short-term Investments | 214M | 408.17M | 281.34M | 174.37M | 156.49M |
| Net Receivables | 17.41M | 40.06M | 37.97M | 41.73M | 50.37M |
| Inventory | 19.26M | 14.45M | 14.45M | 8.44M | 9.82M |
| Other Current Assets | 0 | 9.44M | 11.37M | 11.29M | 13.02M |
| Total Current Assets | 402.75M | 562.15M | 410.19M | 283.75M | 300.19M |
| Property, Plant & Equipment (Net) | 172.94M | 164.21M | 120.32M | 94.38M | 74.72M |
| Goodwill | 118.97M | 118.97M | 118.97M | 118.97M | 118.97M |
| Intangible Assets | 8.53M | 6.83M | 5.13M | 3.43M | 1.73M |
| Long-term Investments | 217.15M | 0 | 0 | 33.66M | 15.92M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.01M | 4.46M | 6.52M | 5.18M | 1.21M |
| Total Non-current Assets | 520.6M | 294.47M | 250.95M | 255.62M | 212.55M |
| Total Assets | 923.34M | 856.62M | 661.13M | 539.38M | 512.74M |
| Account Payables | 3.31M | 8.08M | 7.72M | 7.27M | 6.47M |
| Short-term Debt | 0 | 0 | 0 | 0 | 13.56M |
| Tax Payables | 391K | 194K | 59K | 176K | 0 |
| Deferred Revenue | 80.46M | 64.12M | 48.63M | 55.69M | 45.19M |
| Other Current Liabilities | 15.64M | 15.94M | 13.69M | 16.7M | 7.7M |
| Total Current Liabilities | 113.81M | 109.79M | 88.02M | 98.05M | 89.92M |
| Long-term Debt | 0 | 0 | 0 | 0 | 196.79M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 98.75M | 58.6M | 44.79M | 27.26M | 1.01M |
| Other Non-current Liabilities | 0 | 125.36M | 130.66M | 132.43M | (70.21M) |
| Total Non-current Liabilities | 205.44M | 282.73M | 264.84M | 238.84M | 197.82M |
| Total Liabilities | 319.24M | 392.52M | 352.86M | 336.89M | 287.74M |
| Common Stock | 14K | 14K | 14K | 14K | 15K |
| Retained Earnings | (718.89M) | (919.08M) | (1.14B) | (1.3B) | (1.36B) |
| Accumulated OCI | (1.14M) | (4.12M) | 215K | 166K | 253K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 110K | (67K) | (121K) | (224K) | 6.21M |
| Total Equity | 604.1M | 464.1M | 308.28M | 202.49M | 225M |
| Total Debt | 111.74M | 108M | 98.77M | 89.39M | 280.58M |
| Net Debt | (27.33M) | 17.97M | 33.71M | 41.47M | 210.09M |
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
Intrinsic Alpha fair value
Locked
Current Price
$28.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.